HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Background progenitor activation is associated with recurrence after hepatectomy of combined hepatocellular-cholangiocarcinoma.

AbstractUNLABELLED:
Hepatic progenitor cells (HPC) play important roles in both liver regeneration and carcinogenesis. Combined hepatocellular-cholangiocarcinoma (CHC), a malignant primary liver tumor with poor prognosis, is thought to be of HPC origin. However, the prognostic significance of this etiology is not well defined. Therefore, we retrospectively investigated the relationship of HPC-related pathological features and long-term outcome in patients with CHC in our department. In a cohort of 80 patients identified between 1997 and 2003, including 70 patients who underwent resection with curative intent, overall survival (OS) and disease-free survival (DFS) were correlated with the proliferative activity of nontumor ductular reaction (DR) and the expression levels of HPC and biliary markers including α-fetoprotein (AFP), keratin 7 (K7), keratin 19 (K19), oval cell (OV)-6, epithelial cell adhesion molecule (EpCAM), and c-Kit in both tumor and nontumor liver. We found that nontumor ductular reactions (DRs), specifically the proliferating cell nuclear antigen (PCNA) labeling index of the ductular reaction (PI-DR), a surrogate for transit-amplifying compartments, was an independent prognostic factor for both OS and DFS. By contrast, intratumoral expression of only one marker, absence of AFP, was associated with OS. PI-DR was also independently associated with synchronous "multicentric occurrence" in hepatocellular carcinoma components, a feature of CHC that may predispose to metachronous multifocal tumorigenesis.
CONCLUSION:
Proliferative ductular reaction related to HPC activation is associated with recurrence of CHC. Background HPC activation is strongly associated with multifocal occurrence and related tumor recurrence, highlighting the critical role of background liver disease, a "field effect," in the recurrence of CHC.
AuthorsXiong Cai, Jian Zhai, David E Kaplan, Yijun Zhang, Lining Zhou, Xutao Chen, Guangyang Qian, Qiudong Zhao, Yonghai Li, Lu Gao, Wenming Cong, Minghua Zhu, Zhenlin Yan, Lehua Shi, Dong Wu, Lixin Wei, Feng Shen, Mengchao Wu
JournalHepatology (Baltimore, Md.) (Hepatology) Vol. 56 Issue 5 Pg. 1804-16 (Nov 2012) ISSN: 1527-3350 [Electronic] United States
PMID22684921 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2012 American Association for the Study of Liver Diseases.
Chemical References
  • Antigens, Differentiation
  • Antigens, Neoplasm
  • Biomarkers, Tumor
  • Cell Adhesion Molecules
  • Epithelial Cell Adhesion Molecule
  • Keratin-19
  • Keratin-7
  • Proliferating Cell Nuclear Antigen
  • alpha-Fetoproteins
  • oval cell marker OV-6
  • Proto-Oncogene Proteins c-kit
Topics
  • Adult
  • Analysis of Variance
  • Antigens, Differentiation (metabolism)
  • Antigens, Neoplasm (metabolism)
  • Biomarkers, Tumor (metabolism)
  • Carcinoma, Hepatocellular (metabolism, pathology, surgery)
  • Cell Adhesion Molecules (metabolism)
  • Cholangiocarcinoma (metabolism, pathology, surgery)
  • Disease-Free Survival
  • Epithelial Cell Adhesion Molecule
  • Female
  • Hepatectomy
  • Humans
  • Kaplan-Meier Estimate
  • Keratin-19 (metabolism)
  • Keratin-7 (metabolism)
  • Liver (metabolism)
  • Liver Neoplasms (metabolism, pathology, surgery)
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local (metabolism, pathology)
  • Neoplastic Stem Cells (metabolism)
  • Proliferating Cell Nuclear Antigen (metabolism)
  • Proportional Hazards Models
  • Proto-Oncogene Proteins c-kit (metabolism)
  • ROC Curve
  • Retrospective Studies
  • Statistics, Nonparametric
  • alpha-Fetoproteins (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: